rs587783598
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM2PM5PP2PP3_ModeratePP5_Very_Strong
The NM_001005361.3(DNM2):c.1880C>G(p.Pro627Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. P627H) has been classified as Likely pathogenic.
Frequency
Consequence
NM_001005361.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 15 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DNM2 | NM_001005361.3 | c.1880C>G | p.Pro627Arg | missense_variant | 17/21 | ENST00000389253.9 | NP_001005361.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DNM2 | ENST00000389253.9 | c.1880C>G | p.Pro627Arg | missense_variant | 17/21 | 5 | NM_001005361.3 | ENSP00000373905.4 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Autosomal dominant centronuclear myopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory of Medical Genetics, National & Kapodistrian University of Athens | Sep 21, 2022 | PM1, PM2, PM5, PP3, PP5 - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 17, 2016 | The P627R mutation in the DNM2 gene has been reported previously in an affected mother and daughter who had childhood-onset centronuclear myopathy (CNM). They both had walking difficulties, reduced vital capacity, diffuse muscle weakness, and facial weakness (Bohm et al., 2012). Additionally, another missense mutation at the same position (P627H) and multiple missense mutations in nearby residues (A618T/D, S619L/W, L621P) have been reported in the Human Gene Mutation Database in association with CNM (Stenson et al., 2014). The P627R mutation is a non-conservative amino acid substitution that alters a highly conserved residue predicted to be within the linker domain between the pleckstrin homology (PH) domain and GTPase effector domain (GED) (Bohm et al., 2012). Therefore, the presence of the P672R mutation is consistent with a diagnosis of centronuclear myopathy - |
Centronuclear myopathy Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Feb 08, 2013 | - - |
Charcot-Marie-Tooth disease dominant intermediate B Uncertain:1
Uncertain significance, no assertion criteria provided | literature only | Inherited Neuropathy Consortium Ii, University Of Miami | Jan 06, 2016 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at